Biogen announces Chief Legal Officer departure
Biogen Inc. reported that its Chief Legal Officer, Susan H. Alexander, will leave the company effective at the end of May 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Biogen Inc. reported that its Chief Legal Officer, Susan H. Alexander, will leave the company effective at the end of May 2026. The company has started a search for her successor to lead its legal function. Other aspects of Biogen’s operations are not discussed in this report.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership change did Biogen (BIIB) disclose on March 11, 2026?
Biogen disclosed that Chief Legal Officer Susan H. Alexander will depart effective at the end of May 2026. The company has begun a search for a new Chief Legal Officer to oversee its legal affairs and regulatory responsibilities.
When is Biogen’s Chief Legal Officer Susan H. Alexander scheduled to leave?
Susan H. Alexander is scheduled to depart Biogen at the end of May 2026. This timing provides a transition window for the company as it conducts a search to identify and appoint the next Chief Legal Officer to lead its legal team.
What position is Biogen (BIIB) seeking to fill after this 8-K filing?
Biogen is seeking to fill the role of Chief Legal Officer following the planned departure of Susan H. Alexander. The company has initiated a formal search process to identify a successor to manage its legal, compliance, and governance responsibilities.
Does the Biogen (BIIB) update mention any change to its business operations?
The update focuses solely on the upcoming departure of Chief Legal Officer Susan H. Alexander. It does not describe any direct changes to Biogen’s products, financial results, or broader business operations beyond this executive leadership transition.
Who signed Biogen’s March 11, 2026 leadership change report?
The report was signed on behalf of Biogen Inc. by Wendell Taylor, who is identified as the company’s Secretary. His signature confirms that the disclosure about the Chief Legal Officer’s planned departure is an authorized corporate communication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 11, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
, , Massachusetts 02142
(Address of principal executive offices; Zip Code)
Registrant’s telephone number, including area code: ()
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On March 11, 2026, Biogen Inc. (the “Company”) announced that Susan H. Alexander, Chief Legal Officer, will depart from the Company effective as of the end May,
2026. The Company has initiated a search to identify the Company’s next Chief Legal Officer.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Biogen Inc.
|
||
|
By:
|
/s/ Wendell Taylor
|
|
|
Wendell Taylor
|
||
|
Secretary
|
||
Date: March 11, 2026